The Efficacy and Safety of Utidelone Plus Tirelizumab and Bevacizumab for Advanced or Metastatic Triple-negative Breast Cancer (UTILIZABLE) ：Single-arm, Prospective, Open Clinical Study

This trial is studying a three-drug combination — Utidelone (a chemotherapy), Tirelizumab (an immunotherapy), and Bevacizumab (a drug that cuts off tumor blood supply) — for women with advanced triple-negative breast cancer that has already been treated with standard chemotherapy. **You may be eligible if:** - You are a woman aged 18–70 - You have triple-negative breast cancer (ER negative, PR negative, HER2 negative) confirmed by biopsy - Your cancer is locally advanced or has spread, and has failed or relapsed after at least one chemotherapy regimen - You have at least one measurable tumor - You have good physical functioning (ECOG score 0–1) - Your blood counts, liver, kidney, and thyroid function are within acceptable ranges **You may NOT be eligible if:** - You have had prior anti-VEGF therapy (like Bevacizumab) or prior PD-1/PD-L1 immunotherapy - You have active autoimmune disease - You have uncontrolled high blood pressure - You have had a stroke, blood clot, or heart attack within the past 6 months - You have active HIV, hepatitis B, or hepatitis C - You are pregnant or breastfeeding Talk to your doctor to see if this trial is right for you.